000168426 001__ 168426
000168426 005__ 20260205155159.0
000168426 0247_ $$2doi$$a10.1111/j.1365-2036.2007.03429.x
000168426 0248_ $$2sideral$$a81188
000168426 037__ $$aART-2007-81188
000168426 041__ $$aeng
000168426 100__ $$0(orcid)0000-0001-5932-2889$$aLanas, A$$uUniversidad de Zaragoza
000168426 245__ $$aEffects of long-term cyclo-oxygenase 2 selective and acid inhibition on Barrett's oesophagus
000168426 260__ $$c2007
000168426 5203_ $$aBackground: There is an overexpression of cyclo-oxygenase 2 (COX-2) in Barrett’s oesophagus (BO). Aim To determine the long-term effect of a COX-2 inhibitor on cellular mechanisms involved in BO.
Methods: A randomized controlled trial was conducted in BO patients allocated to continue the usual proton pump inhibitor (PPI) alone treatment, or PPI combined with rofecoxib (25 mg/ day) for 6 months. Cell proliferation index and COX-2 expression in BO glands was determined in biopsy specimens at baseline and after treatment. Cell apoptosis, cyclin D1, p53 and vascular endothelial growth factor (VEGF) expression was also explored in a subset of patients. Student-t test and the U-Mann–Whitney test were used for quantitative and ordinal variables.
Results: Of 62 patients, 58 completed the study. A higher proportion of patients on rofecoxib + PPI exhibited a decrease in COX-2 expression compared to those treated with PPI alone, but cell proliferation index was not affected. Unlike PPI alone, rofecoxib + PPI was associated with an increase in the apoptotic cell index, a decrease in p53 cell staining and VEGF expression in mucosal vessels. No effect on low-grade dysplasia or cyclin D1 was observed.
Conclusions: The addition of rofecoxib to PPI therapy does not affect cell proliferation index in BO cells after 6 months of therapy, but does reduce COX-2 and VEGF expression and increases cell apoptosis.
000168426 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000168426 590__ $$a3.201$$b2007
000168426 591__ $$aPHARMACOLOGY & PHARMACY$$b55 / 203 = 0.271$$c2007$$dQ2$$eT1
000168426 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b16 / 50 = 0.32$$c2007$$dQ2$$eT1
000168426 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000168426 700__ $$0(orcid)0000-0002-3869-8235$$aOrtego, J$$uUniversidad de Zaragoza
000168426 700__ $$0(orcid)0000-0002-8678-4680$$aSopeña, F$$uUniversidad de Zaragoza
000168426 700__ $$0(orcid)0000-0001-6522-6682$$aAlcedo, J
000168426 700__ $$0(orcid)0000-0001-5603-3045$$aBarrio, E
000168426 700__ $$aBujanda, L
000168426 700__ $$aCosme, A
000168426 700__ $$0(orcid)0000-0002-1732-2941$$aBajador, E$$uUniversidad de Zaragoza
000168426 700__ $$aParra-Blanco, A
000168426 700__ $$0(orcid)0000-0003-2280-9372$$aFerrandez, A
000168426 700__ $$0(orcid)0000-0001-5813-3445$$aPiazuelo, E
000168426 700__ $$aQuintero, E
000168426 700__ $$aPique, JM
000168426 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000168426 7102_ $$11000$$2020$$aUniversidad de Zaragoza$$bDpto. Anat.Pat.Med.Leg.For.To.$$cArea Anatomía Patológica
000168426 773__ $$g26, 6 (2007), 913-923$$pAliment. pharmacol. ther.$$tALIMENTARY PHARMACOLOGY & THERAPEUTICS$$x0269-2813
000168426 8564_ $$s1187572$$uhttps://zaguan.unizar.es/record/168426/files/texto_completo.pdf$$yVersión publicada
000168426 8564_ $$s1842132$$uhttps://zaguan.unizar.es/record/168426/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000168426 909CO $$ooai:zaguan.unizar.es:168426$$particulos$$pdriver
000168426 951__ $$a2026-02-05-14:36:19
000168426 980__ $$aARTICLE